Floatz logo

Hycamtin

Malignant Ovarian Serous Tumor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Malignant Ovarian Serous Tumor cohort.

Asset / SponsorPhaseRating
N-Acetyl-L-Cysteine
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2CCC
Sargramostim
Barbara Ann Karmanos Cancer Institute
Phase 1CC
her2bi-armed activated t cells
Barbara Ann Karmanos Cancer Institute
Phase 1C

Same molecule, other indications

Hycamtin is also rated in:

primary peritoneal carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
non-small cell lung carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →